Treatment News

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News


September 28, 2012
Atripla, Sustiva Component Linked to Neuron Damage
A byproduct formed during the breakdown of efavirenz, found in Sustiva and Atripla, appears to damage nerve cells, according to new Johns Hopkins University research. 
Comprehensive Care, Ryan White Funding, Means Survival Benefits at Inner-City Clinic
At an inner city Baltimore HIV clinic serving a primarily poor and black population, the average life expectancy is now 73 years, according to a new 15-year analysis of patient outcomes reported by Johns Hopkins University researchers in Clinical Infectious Diseases. Importantly, long-term survival at the clinic was highly dependent on comprehensive disease management—a mix of expert primary, specialty and supportive health care services—underscoring the importance of funding streams like Ryan White to provide vital resources. 
September 27, 2012
Consistent and Correct Condom Use Required to Reduce Non-Viral STI Risk
Latex condoms need to be used both consistently and correctly to reduce the risk of becoming infected with some common non-viral sexually transmitted infections.
Life-Threatening Meningitis Cluster in NYC HIV+ Men Sparks Warning
The New York City Department of Health and Mental Hygiene investigating a cluster of potentially lethal invasive meningococcal disease among HIV-positive gay men.
September 25, 2012
Pain Means HIV Clinic Appointment No-Shows in Alabama Study
Not only is pain common among people living with HIV, it increases the odds of no-show clinic visits, according to a new University of Alabama, Birmingham (UAB), study. 
September 24, 2012
CD4 Counts Not Affected by Alcohol Consumption
Consuming alcohol doesn’t appear to have a deleterious effect on CD4 cell counts among people living with HIV receiving antiretroviral therapy, according to a new Johns Hopkins University study.
September 21, 2012
Thalidomide for HIV-Related IRIS Shows Promise
Thalidomide, a historically controversial drug, may hold potential for people living with HIV who experience immune reconstitution inflammatory syndrome (IRIS) and do not respond favorably and quickly to corticosteroids like prednisone, according to a small series of case reports published online ahead of print by the journal AIDS. 
September 20, 2012
Boehringer Ingelheim Exits Virology Research
Boehringer Ingelheim, a Germany-based company known for its successful development of two HIV drugs and ongoing study of two hepatitis C medications, is discontinuing its virology research program.
September 19, 2012
People With HIV Face Higher Risk of Death Following Heart Attack
HIV-positive people who experience a heart attack and require hospitalization are more likely to die, compared with those not infected with the virus, according to nationwide survey data.
September 18, 2012
Common Application Now Available for HIV Patient Assistance Programs
The Common Patient Assistance Program Application (CPAPA), announced by Health and Human Services (HHS) Secretary Kathleen Sebelius at the International AIDS Conference in July is now in effect.
Stribild Receives 'Alternative' U.S. Guidelines Ranking
U.S. HIV treatment guidelines classify Stribild, formerly known as the Quad, as an 'alternative' regimen option for first-time treatment takers. 
September 17, 2012
Dolutegravir Regimen Bests Atripla as First-Line HIV Therapy
Dolutegravir, an experimental once-daily integrase inhibitor being developed by ViiV Healthcare and Shionogi, combined with Epzicom, appears to have an efficacy advantage over Atripla among people starting HIV treatment for the first time. 
Sofosbuvir (GS-7977) Shows Promise in HIV/Hep C-Coinfected People
Gilead Sciences' experimental NS5B polymerase inhibitor sofosbuvir (GS-7977) rapidly reduced hepatitis C virus (HCV) levels in people coinfected with HIV in a small seven-day study.
September 07, 2012
Black Women With HIV and Hep C Less Likely to Die of Liver-Related Disease
Black women living with HIV and hepatitis C virus (HCV) are less likely to die of liver disease, compared with white and Latina women coinfected with both viruses, according to a new analysis of the federally funded Women’s Interagency HIV Study (WIHS) published online ahead of print by the journal Hepatology. 
September 06, 2012
HIV Treatment Increasing Among Those in Care in U.S.
Among people engaged in HIV care in the United States, rates of antiretroviral therapy usage and undetectable viral loads increased substantially between 2000 and 2008, according to new data from the NA-ACCORD study.
Gilead Sciences, Task Force Agree to ADAP Price Discount for Stribild
The AIDS Drug Assistance Program (ADAP) purchase price for the newly approved fixed-dose combination tablet Stribild will be substantially lower than the announced $28,500 wholesale acquisition cost (WAC), as a result of a new pricing agreement reached between Gilead Sciences and the ADAP Crisis Task Force. 
Crofelemer for HIV Diarrhea Delayed Again by FDA
The U.S. Food and Drug Administration (FDA) has again postponed a decision on approving crofelemer, a compound made from the sap of the Peruvian Dragon’s Blood tree for the treatment of diarrhea in people living with HIV receiving antiretroviral therapy.
September 05, 2012
Too Few People With HIV Take Aspirin to Prevent Heart Attacks and Strokes
Most HIV-positive people who should be taking aspirin to prevent a heart attack or stroke are not doing so, according to a University of Alabama at Birmingham (UAB) study published online ahead of print by Clinical Infectious Diseases. In fact, fewer than one in five who met the U.S. criteria for aspirin therapy were taking advantage of the cheap, over-the-counter medication.
September 04, 2012
Norvir-Boosted Reyataz Linked to High Kidney Stone Risk
People living with HIV using Norvir (ritonavir)-boosted Reyataz (atazanavir) were roughly ten times more likely to experience kidney stones, compared with those using other Norvir-boosted protease inhibitor (PI)-based regimens, according to a review of patient data conducted by Japanese researchers.
More Treatment News

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ



Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    aqua_31206
    Macon
    Georgia


    TanyaB
    Delray Beach
    Florida


    ernienyc
    Bronx
    New York


    RayOctober
    Richmond
    Virginia
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Can social media help stop HIV stigma?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.